Comparative bronchial responses to hyperosmolar saline and methacholine in asthma

L-P Boullet, C Legris, L Thibault, H Turcotte

From the Centre de Pneumologie, Hôpital Laval, Ste-Foy, Quebec, Canada

ABSTRACT  Airway responsiveness to inhaled methacholine and to ultrasonically nebulised hyperosmolar saline was compared in 20 asthmatic subjects. Each subject had two hyperosmolar inhalation tests and a methacholine challenge in random order at least 48 hours apart over a period of two weeks. Hyperosmolar challenge, carried out with doubling concentrations of saline from 0-9% to 14-4% to obtain a dose-response curve, was well tolerated by all subjects. The response to hyperosmolar saline—expressed as the PO_{20}, the osmolarity inducing a 20% fall in forced expiratory volume in one second (FEV_{1})—was obtained in 16 of the 20 subjects and in each was repeatable to within one doubling concentration of saline. The peak bronchoconstrictor effect of hyperosmolar saline inhalation occurred at 3 minutes and its mean total duration (FEV_{1} < 90% of baseline) was 50 minutes. There was no significant correlation between the PO_{20} and the PC_{20} methacholine (the concentration inducing a 20% fall in FEV_{1}). Thus by using a new method to obtain a quantitative airway response to inhaled hyperosmolar saline we found that the airway response to hyperosmolar inhalation differs from the airway response to methacholine.

The inhalation of hyposmolar or hyperosmolar solutions may induce bronchoconstriction in asthmatic subjects and provides a new method to investigate non-specific bronchial responsiveness. It has been suggested that this type of bronchial provocation test may be useful in the diagnosis and evaluation of asthma and for studying the mechanisms of exercise induced asthma. The hyperosmolar inhalation test, however, has not been standardised and little is known about the mechanisms by which it induces bronchoconstriction.

Findlay and colleagues have shown that hyperosmolar stimulation can induce the release of histamine from human basophils. Both hypo-osmolar and hyperosmolar solutions of glucose and saline produced bronchoconstriction in patients with mild asthma, whereas an ion free iso-osmolar solution did not reduce expiratory flow rate. Pretreatment with nebulised sodium cromoglycate reduced the response to 3-6% saline, suggesting that chemical mediators may be released from mast cells in response to hyperosmolar challenge.

There have been reports of some degree of correlation between the airway responses to different non-specific stimuli, such as exercise and inhaled histamine, isocapnic hyperventilation of cold air and inhaled methacholine or ultrasonically nebulised water, and the inhalation of distilled water and exercise. Little, however, is known about the relationship between the bronchial response to hyperosmolar solutions and other bronchoconstrictor stimuli.

This study was designed to develop a method to measure non-specific bronchial reactivity to hyperosmolar solutions in a dose-response manner, to verify its reproducibility, to examine tolerance to high concentrations of saline, and to compare the airway response to hyperosmolarity with the response to inhaled methacholine in the same subjects.

Methods

Twenty patients with asthma as defined by the American Thoracic Society (10 of them women), aged 17–48 years, took part to the study (table 1). Their asthma was mild to moderate, with PC_{20} values (provocative concentrations of methacholine giving a 20% fall in the forced expiratory volume in one second (FEV_{1})) ranging from 0-19 to 6-73 mg/ml. Asthma
Characteristics of the subjects

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Atopy*</th>
<th>FEV₁ (% pred)</th>
<th>FVC (% pred)</th>
<th>PC₂₀ methacholine (mg/ml)</th>
<th>PO₂₀ saline (mmol/l)</th>
<th>Current medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>44</td>
<td>F</td>
<td>0</td>
<td>2.25 (74)</td>
<td>3.45 (88)</td>
<td>0.66 (2.5)</td>
<td>1.091 (1.5)</td>
<td>B₂ T B</td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>F</td>
<td>5</td>
<td>2.89 (89)</td>
<td>4.13 (103)</td>
<td>2.86 (1.31)</td>
<td>6410 &gt;4610 B₂</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>22</td>
<td>F</td>
<td>7</td>
<td>2.82 (96-6)</td>
<td>3.47 (98-5)</td>
<td>4.34 (2.09)</td>
<td>674.5 &gt;869</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>19</td>
<td>F</td>
<td>11</td>
<td>2.77 (82)</td>
<td>3.62 (97-8)</td>
<td>0.53 (0.46)</td>
<td>2737.2 3541-1</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>21</td>
<td>F</td>
<td>0</td>
<td>3.67 (107-9)</td>
<td>4.26 (107-7)</td>
<td>4.5 (5.28)</td>
<td>4610 &gt;4610 B₂ T B</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>29</td>
<td>M</td>
<td>13</td>
<td>3.60 (81)</td>
<td>5.15 (90-5)</td>
<td>0.55 (1.09)</td>
<td>1325-3 1249-0 B₂</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>32</td>
<td>M</td>
<td>7</td>
<td>3.55 (87-4)</td>
<td>4.78 (92-4)</td>
<td>2.69 (1.06)</td>
<td>1321-3 1249-0 B₂</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>48</td>
<td>M</td>
<td>5</td>
<td>3.39 (63-9)</td>
<td>4.55 (89-9)</td>
<td>0.33 (0.64)</td>
<td>701-0 473-4 B₂ T</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>43</td>
<td>M</td>
<td>0</td>
<td>3.28 (93-9)</td>
<td>4.75 (104-8)</td>
<td>2.06 (1.62)</td>
<td>3217-0 2441-7 B₂ T B</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>25</td>
<td>F</td>
<td>8</td>
<td>2.95 (89-6)</td>
<td>3.71 (90-3)</td>
<td>0.23 (0.20)</td>
<td>656-6 755-7 B₂</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>24</td>
<td>F</td>
<td>6</td>
<td>3.50 (94-6)</td>
<td>4.86 (108-7)</td>
<td>0.57 (0.50)</td>
<td>724-8 1391-7 B₂</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>37</td>
<td>M</td>
<td>4</td>
<td>3.04 (75-4)</td>
<td>4.53 (88-0)</td>
<td>0.19 (0.13)</td>
<td>999-4 1452-9 B₂</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>29</td>
<td>M</td>
<td>9</td>
<td>3.78 (85-5)</td>
<td>5.32 (97-3)</td>
<td>1.25 (1.31)</td>
<td>1594-9 2282-3 B₂</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>43</td>
<td>M</td>
<td>1</td>
<td>2.99 (84-7)</td>
<td>4.31 (93-5)</td>
<td>4.20 (2.65)</td>
<td>4610 &gt;4610 B₂ T B</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>21</td>
<td>F</td>
<td>2</td>
<td>3.20 (96-1)</td>
<td>4.15 (107-8)</td>
<td>4.43 (4.22)</td>
<td>867-6 1426-7 B₂</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>40</td>
<td>M</td>
<td>1</td>
<td>3.75 (102-2)</td>
<td>4.78 (101-3)</td>
<td>6.73 (3.86)</td>
<td>1320-9 1221-2 B₂</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>19</td>
<td>F</td>
<td>2</td>
<td>3.18 (93-0)</td>
<td>3.68 (94-4)</td>
<td>1.08 (0.86)</td>
<td>1203-7 1224-4 B₂</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>33</td>
<td>M</td>
<td>0</td>
<td>3.47 (101-8)</td>
<td>4.30 (103-4)</td>
<td>1.27 (2.47)</td>
<td>4610 &gt;4610 B₂</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>21</td>
<td>M</td>
<td>9</td>
<td>3.79 (85-5)</td>
<td>4.69 (100-0)</td>
<td>0.41 (0.37)</td>
<td>471-5 576-2 B₂</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>18</td>
<td>F</td>
<td>12</td>
<td>3.58 (105-5)</td>
<td>4.14 (105-6)</td>
<td>5.54 (6.1)</td>
<td>849-9 856-0 B₂</td>
<td></td>
</tr>
</tbody>
</table>

*Number of positive weal and flare responses (>2 mm) to a battery of common allergens. T—theophylline; B₂ β₂ agonists; B₂ beclomethasone.

Symptoms were controlled by an inhaled β₂ agonist as required; five subjects were taking theophylline and four ipratropium bromide. Patients with a past history of cardiovascular disease, recent unstable asthma, or respiratory infection in the last month were excluded from the study. No subject was currently exposed to an antigen to which he was known to be sensitised. The study was approved by the hospital ethics committee and all subjects signed a consent form.

**STUDY DESIGN**

Subjects attended the laboratory on four occasions during two weeks. The visits were separated by at least 48 hours and tests were performed at the same time on each day. Long acting theophyllines were stopped for 48 hours, and inhaled adrenergic or anticholinergic drugs for eight hours before each test. Baseline FEV₁ had to be greater than 60% of predicted at each visit; if it was not, the test was postponed.

The initial evaluation included measurement of FEV₁ and forced vital capacity (FVC) with the vitalograph spirometer (S model) and of bronchial responsiveness to methacholine, by the method described by Cockcroft et al. On the three subsequent visits a methacholine inhalation test and two hyperosmolar challenges were performed in a randomised, double blind order. After each test subjects were asked to record the occurrence of respiratory symptoms.

**METHACHOLINE INHALATION TESTS**

After the measurement of baseline FEV₁ and FVC, the subject inhaled a control solution of saline 0·9% followed by doubling concentrations of methacholine (0·03–8 mg/ml) until a 20% fall in FEV₁ occurred. FEV₁ was measured at 30, 90, and 180 seconds and repeated if necessary every two minutes until it started to increase. Methacholine was inhaled for two minutes at five minute intervals, and the bronchial response,
Comparative bronchial responses to hyperosmolar saline and methacholine in asthma

expressed as the PC20 FEV1 was obtained by interpolation of the last two points of the dose-response curve. Aerosols were generated by a Wright nebuliser operating at 345 kPa (50 lb/in²) and 71 min⁻¹ to get a constant aerosol output of 0·13 ml/min⁻¹.

HYPEROSMOLAR CHALLENGES

Aerosols of hyperosmolar saline were generated by a MystO2gen ultrasonic nebuliser operating at 3·6 l min⁻¹ and calibrated to produce an aerosol output of 2·0 (SD 0·3) ml/min. Hyperosmolar saline was prepared by dilution of commercial sterile preservative free saline 3% or 14·6%. A 20 ml volume of each concentration of saline was placed in the nebuliser container in turn. Aerosols were inhaled via a mask held loosely over the face for periods of five minutes at five minute intervals, so that a total of 10 ml of each concentration of saline was nebulised. If the fall in FEV1 was under 20% the next concentration was given five minutes later. After measurement of baseline FEV1 and FVC, subjects inhaled solutions of sodium chloride 0·9%, 1·8%, 3·6%, 7·2% and 14·4% as required; the solutions corresponded to osmolalities of 280, 560, 1062, 2222 and 4610 mmol (mosm)/kg. Osmolarity was measured with an osmometer MicroOsmette (Precisions Systems Inc, Massachusetts, Model 5004). Ionic concentration and density of hyperosmolar solutions measured before and after nebulisation were similar except for the last concentration (14·4%), where there was a slight increase in density after nebulisation (< 10% of its initial density). The bronchial response was determined by measurement of FEV1 at 30, 90, and 180 seconds after the inhalation and every two minutes until it started to increase. The test was stopped when a 20% fall in FEV1 was obtained or when the highest concentration of saline (14·4%) had been given. The PO20, the osmolality causing a 20% fall in FEV1, was determined by interpolation of the last two points of the log dose-response curve.

TIME COURSE OF RESPONSE TO HYPEROSMOLAR CHALLENGE

To determine the time course of hyperosmolar induced bronchoconstriction, FEV1 was measured every two minutes for the first 15 minutes after the last inhalation of hyperosmolar saline and then every five minutes for one hour. If symptoms persisted after one hour, 200 µg inhaled salbutamol was administered.

The peak action was defined as the maximum fall in FEV1 obtained after the last inhalation of hyperosmolar saline, and the plateau as the time the FEV1 remained within 10% of the peak value. The mean recovery time was the interval between the peak action and return of the FEV1 to within 90% of baseline.

**STATISTICAL ANALYSIS**

All analyses were carried out on logarithmically transformed PO20 and PC20 values. Differences between the two PO20 saline and the two PC20 methacholine values were analysed with paired t tests. The differences between the results of the two hyperosmolar challenges were plotted against their mean value to assess the repeatability of the tests. To determine whether PC20 methacholine was correlated with PO20 saline a linear regression analysis was performed.

**Results**

All 20 subjects studied completed the study. The responses to the challenges are summarised in table 2. The side effects of hyperosmolar saline were similar to those of methacholine—transient cough, hypersecretion, and mild dyspnoea. After the study no increase in asthma symptoms or need to increase medication was reported apart from some continuing hypersecretion for a few hours after the osmolar challenge. Serum sodium concentrations, measured in four subjects after 10 minutes' inhalation of 14·4% saline, were unchanged.

A PO20 saline value was obtained in 16 of the 20 subjects; in the other four even the highest concentration (14·4%) did not induce a fall in FEV1. Figure 1 shows the relation between the PO20 values from the two hyperosmolar tests. The difference in geometric mean PO20 values was not significant (p > 0·05). The
PO$_{20}$ values were within one doubling osmolarity dose of saline for all 16 subjects. The difference in response to the two hyperosmolar challenges was not related to the mean PO$_{20}$ value.

The response to methacholine inhalation, as expressed by the PC$_{20}$ value, was repeatable. The PC$_{20}$ values were within one doubling concentration of methacholine in 15 subjects and within two doubling concentrations in four subjects. One subject had only one test. There was no significant correlation between the mean PC$_{20}$ methacholine and PO$_{20}$ saline ($r = 0.168$, $p > 0.05$; figure 2).

Figure 3 shows the pattern of change in FEV$_1$ after hyperosmolar challenge. The peak action occurred at 3 minutes, the plateau duration was 17 minutes, the mean recovery time was 47 minutes, and the total duration of action was 50 minutes.

**Discussion**

In this study we used a new method to measure the bronchial responsiveness to hyperosmolar solutions in a dose-response manner. A 20% fall in FEV$_1$ was obtained in 80% of the subjects after inhalation of hyperosmolar saline in concentrations up to 14.4%. The different concentrations of saline represented substantial ionic change, sufficient to allow discrimination between the degrees of response to hyperosmolar saline among different asthmatic subjects. The test was simple, well tolerated, and reproducible. The degree of agreement found within one doubling dose for all measurements is acceptable. In a further study some of these subjects have been rechallenged with hyperosmolar saline by the same method and similar results have been obtained, confirming the reproducibility of the test. We did not test elderly patients or subjects with cardiovascular disease. The amount of sodium chloride introduced into the airways is small, however, and should not be harmful. Serum sodium concentrations were unchanged after inhalation of the highest concentration of saline.

We compared bronchial responsiveness to hyperosmolar solutions and to methacholine. Methacholine challenges showed a good degree of reproducibility, the PC$_{20}$ values recorded being within a 3-2 fold concentration as reported previously.

The fall in FEV$_1$ after hyperosmolar induced bronchoconstriction was prolonged (50 minutes), and similar to the time course described for methacholine. In the few patients who required inhaled salbutamol (200 µg) after the study the bronchoconstriction was completely reversed.

![Graph](image-url)
Comparative bronchial responses to hyperosmolar saline and methacholine in asthma

Our results confirm the findings of previous studies showing that inhalation of hyperosmolar solution causes bronchoconstriction in asthmatic subjects. There was no correlation between the response to hyperosmolar solution and the response to methacholine. The hyperosmolar stimulus thus appears to differ from the other non-specific stimuli such as cold air, exercise, PGF$_2\alpha$, histamine, and methacholine since these have been shown to be correlated.

The response to methacholine and histamine has been shown to be related to the severity of asthma and the amount of medication required to control symptoms. This does not seem to be the case with hyperosmolar solutions, since there was no correlation between the PO$_{20}$ and the severity of asthma, as assessed by baseline expiratory flow rates, medication needed to control asthma, or the PC$_{20}$ methacholine. This suggests that the mechanism underlying the response to hyperosmolar solutions is different in the asthmatic population.

One of the main hypotheses to explain exercise induced asthma is that airway secretions become hyperosmolar during hyperventilation. We are therefore investigating the bronchial response to hyperosmolar saline and exercise. A correlation between the bronchial response to inhalation of hyperosmolar solution and exercise has been reported. Further studies are required to determine the consequences of airway dehydration in different situations and the role of mediators of inflammation in the development of bronchoconstriction induced by this stimulus.

In conclusion, we describe a new method of bronchoprovocation with hyperosmolar saline. This method is simple, reproducible, and safe. There was no correlation between the bronchial response to hyperosmolarity and the response to methacholine. This test may be of limited usefulness in the evaluation of non-specific bronchial reactivity or the degree of severity of asthma, but is an interesting tool to study the effect of osmolar changes in the airways, particularly in relation to exercise induced asthma.

This work was supported by a grant from the Medical Research Council of Canada.

References

1 Anderson SD, Schoeffel RE, Finney M. Evaluation of


Comparative bronchial responses to hyperosmolar saline and methacholine in asthma.
L P Boulet, C Legris, L Thibault and H Turcotte

Thorax 1987 42: 953-958
doi: 10.1136/thx.42.12.953

Updated information and services can be found at:
http://thorax.bmj.com/content/42/12/953

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/